GlassScriptPhysician profile
Jamie T Miller
NPI 1184646630
$18,423.58
in general payments reported to CMS, 2019-2025
34 companies · $3,038 in 2025
The $3,038 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,553 · 2022: $4,757 · 2023: $4,040 · 2024: $3,036 · 2025: $3,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,949 · Travel and Lodging: $1,094 · Gift: $59.40 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,949.33 |
| Travel and Lodging | $1,093.86 |
| Gift | $59.40 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $4,599.29 | 2021-2025 | Afrezza |
| Medtronic, INC. | $2,863.75 | 2021-2025 | Minimed 780g, Minimed 770g, Guardian Sensor (3) |
| Novo Nordisk INC | $1,646.34 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,107.14 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $1,003.04 | 2021-2025 | |
| Corcept Therapeutics | $1,001.39 | 2021-2025 | Korlym |
| Lilly USA, LLC | $963.68 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Insulet Corporation | $717.41 | 2021-2025 | Omnipod |
| Abbott Laboratories | $651.60 | 2021-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $624.01 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $604.94 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $396.08 | 2023-2025 | |
| Abbvie INC. | $375.72 | 2021-2025 | |
| Beta Bionics, INC. | $366.60 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amgen INC. | $257.87 | 2021-2025 | Tepezza, Repatha |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $187.87 | 2021-2022 | |
| Kyowa Kirin, INC. | $124.06 | 2023-2025 | Crysvita |
| Radius Health, INC. | $117.87 | 2023-2025 | Tymlos |
| Horizon Therapeutics Plc | $113.54 | 2021-2023 | Tepezza |
| Amarin Pharma, INC. | $111.22 | 2021 | |
| Astellas Pharma US INC | $104.52 | 2023-2025 | Veozah |
| Dexcom, INC. | $73.30 | 2021-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $72.36 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $67.64 | 2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $45.45 | 2021 | |
| Amryt Pharma Holdings LTD | $35.25 | 2021 | |
| Clarus Therapeutics INC. | $34.84 | 2021 | |
| Alexion Pharmaceuticals, INC. | $34.59 | 2021-2022 | |
| Pfizer INC. | $26.75 | 2021 | |
| Ibsa Pharma INC. | $25.50 | 2021 | |
| Averitas Pharma INC. | $17.95 | 2023 | Qutenza |
| Ascensia Diabetes Care US INC. | $17.74 | 2025 | |
| Sequel Med Tech, LLC | $17.56 | 2025 | Twiist |
| Zealand Pharma US, INC. | $16.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.